Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

InnoCare Pharma Limited
諾誠健華醫藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9969)

VOLUNTARY ANNOUNCEMENT

APPROVAL OF ORELABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA IN AUSTRALIA

This announcement is made by InnoCare Pharma Limited (the "**Company**") on a voluntary basis to inform shareholders and potential investors of the Company's latest business developments.

The Board of Directors (the "**Board**") is pleased to announce that orelabrutinib (宜諾凱®, HIBRUKA®) has been approved by the Therapeutic Goods Administration (TGA) in Australia for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL).

MCL is a distinct subtype of B-cell non-Hodgkin lymphoma (NHL). It is an aggressive and currently incurable disease with rising incidence. Patients are often diagnosed at an advanced stage with limited treatment options and poor prognosis.

Orelabrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor developed by the Company for the treatment of cancers and autoimmune diseases. Its high target selectivity minimizes off-target effects, thereby improving both safety and efficacy.

Previously orelabrutinib has been approved for the treatment of four indications in China, including first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), relapsed and refractory CLL/SLL, r/r MCL and relapsed and refractory marginal zone lymphoma (r/r MZL), all of which have been covered in the National Reimbursement Drug List. Globally, orelabrutinib has been approved in Singapore for the treatment of adult patients with r/r MCL and r/r MZL.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately commercialize orelabrutinib for the treatment of r/r MCL in Australia successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 27 May 2026

As at the date of this announcement, the Board comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi and Mr. Ronggang Xie as non-executive Directors, and Ms. Lan Hu, Dr. Dandan Dong and Prof. Kunliang Guan as independent non-executive Directors.